Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V

   published on

   01.07.2024

   Document type

   PDF document, 513 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-36_en

   Download file : Extract of dossier assessment (PDF document, 513 kB, EN, not accessible)
2. Dossier assessment

   Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V

   published on

   01.07.2024

   Document type

   PDF document, 944 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-36

   Download file : Dossier assessment (PDF document, 944 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A24-36

Commission

Commission awarded on 02.04.2024 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Head and nerves

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-36_en

Connected Projects

1. Dossier assessment

   Efgartigimod alfa (Chronic inflammatory demyelinating polyneuropathy) – Benefit assessment according to § 35a SGB V

   Project no.

   A25-95

   Last updated

   03.11.2025

   Status: Commission completed